Philip Morris International Progresses Towards Smoke-Free Future

Sep.16.2022
Philip Morris International Progresses Towards Smoke-Free Future
PMI aims to end cigarette sales and promote smoke-free alternatives, with decreasing sales and increasing investment in innovation products.

PMI is often asked if it truly intends to end cigarette sales.


The answer is: yes.


Philip Morris International acknowledges that the decline in cigarette sales - or broadly speaking, the decline in the combustible product portfolio of PMI - is a necessary component in achieving its ambitions for a smoke-free future.


Fimo International is rapidly making progress towards this goal.


According to data publicly released by Fumo International, their cigarette sales have been on a downward trend for the past decade.


The annual sales volume of cigarettes has declined from 91.5 billion units in 2011 to 62.5 billion units in 2021, decreasing every year over the past nine years.


Furthermore, PMI has set a target for the total shipment of combustible products to be below 550 billion units by 2025, as stated in their 2021 comprehensive report.


The cigarette shipments of PMI (Phillip Morris International) have decreased from 915 billion in 2011 to 625 billion in 2021.


Phimo International aims to ultimately replace cigarettes with smoke-free alternatives.


Since 2008, Philip Morris International has invested over 9 billion dollars in the research and development, product development, production capabilities, scientific validation, and understanding of adult smokers for these innovative products.


This is a successful investment as an increasing number of adult smokers are switching to FiMO International's heated tobacco products, leading to a reduction in cigarette transportation volume.


As of June 30th, 2022, approximately 13.2 million adult smokers have switched to smoke-free alternatives and quit smoking.


The shipment volume of PhiMo International's heated tobacco devices has increased from 7 billion in 2016 to 95 billion in 2021.


These figures are transparently released annually by Fimo International for anyone to access.


Although the optimal choice for any smoker is to completely quit smoking and nicotine, scientifically proven smokeless products are a better option for adult smokers who would otherwise continue smoking.


According to Moira Gilchrist, VP of Strategic and Scientific Communication at Philip Morris International, the company's decision to unilaterally stop selling cigarettes tomorrow will not change anything. "Because it doesn't eliminate the demand for cigarettes. The demand will remain, and others will simply fill it, whether it be competitors or participants in the black market.


Our transition is more significant because we are striving to reduce the long-term demand for cigarettes, ensuring that the decline in the number of smokers continues - and may even accelerate further.


These numbers cannot be ignored," said Stefano Volpetti, President of the PMI Smoke-Free Products category and Chief Consumer Officer. "They clearly depict the transformation that Philip Morris International is driving - first, providing a range of better alternatives for adult smokers and secondly, accelerating smoking cessation.


Our scientific evidence confirms that PMI's smoke-free products, while not without risk, are a better choice than cigarettes for adults who would otherwise continue to smoke.


With support from the industry, stakeholders, and civil society, we believe that cigarette sales can come to an end in many countries within 10 to 15 years. This would be an enduring achievement for the global population of 1 billion smokers, global public health, and our company.


As of June 30, 2022, Philip Morris International (PMI) estimates that approximately 13.2 million adult individuals worldwide (excluding Russia and Ukraine) have switched to their heated tobacco products and quit smoking. These user statistics are reflective of PMI's estimates, which are based on consumer statements and sample-based statistical evaluations, with an average margin of error of +/-5% within the 95% confidence interval in key quantity markets. The accuracy and reliability of user statistics may vary depending on the maturity of individual markets and the availability of information.


Statement:


The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The translation of this article is for industry exchange and research purposes only.


Due to the limitations of the translator's skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS’ viewpoints and statements on any domestic, Hong Kong, Macau, Taiwan, or international issues are entirely aligned with those of the Chinese government.


The copyright of compiled information belongs to the original media outlet and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
British American Tobacco's Japanese subsidiary, BAT Japan, launched VELO Mango Ice Medium on November 2, 2026, with distribution expanding to selected 7-Eleven, FamilyMart, NewDays and Seicomart stores from November 3. The new oral tobacco product contains 15 pouches per can and retails for ¥380, featuring a mango and cooling flavor profile at Medium intensity. At the same time, BAT Japan raised prices on multiple existing VELO products from ¥360 to ¥380 per can and withdrew selected SKUs from convenience store distribution without discontinuing them entirely. The changes affect product assortment, pricing and retail channel allocation.
product
Nov.04
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma passed a government-sponsored amendment on November 11, 2026, by 414 votes to none, seeking to prevent businesses from classifying information on the presence and number of types of certain harmful ingredients in tobacco and nicotine-containing products as trade secrets. The measure covers ingredients capable of increasing nicotine dependence or exhibiting toxic, carcinogenic, mutagenic or reproductive toxicity, including substances that acquire such properties during heating or smoldering. Bill No. 1286415-8 would amend Article 5 of Federal Law No. 98-FZ on Commercial Secrets and is scheduled to take effect on January 1, 2027. The bill has cleared all three readings in the State Duma but has not completed the remaining legislative procedures.
Regulations
Nov.12 by 2Firsts Perspectives
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives